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Purpose: A post hoc analysis of a recent trial on direct oral anticoagulants versus vitamin K 
antagonists showed that amongst patients with mildly decreased kidney function, use of vitamin 
K antagonists was associated with a greater decline in renal function than use of direct oral 
anticoagulants. Whether these vitamin K antagonist effects are the same in pre-dialysis patients 
is unknown. Therefore, the aim of this study was to investigate the association between vitamin 
K antagonist use and the rate of renal function decline and time until start of dialysis in incident 
pre-dialysis patients. 
Methods: Data from 984 patients from the PREdialysis PAtient REcord study, a multicenter 
follow-up study of patients with chronic kidney disease who started pre-dialysis care in the 
Netherlands (1999–2011), were analyzed. Of these patients, 101 used a vitamin K antagonist. 
Linear mixed models were used to compare renal function decline between vitamin K antagonist 
users and non-users. Cox proportional hazards models were used to estimate the HR with 95% 
CI for starting dialysis.
Results: Vitamin K antagonist use was associated with an extra change in renal function of 
–0.09 (95% CI –1.32 to 1.13) mL/min/1.73 m2 per year after adjustment for confounding. The 
adjusted HR for the start of dialysis was 1.20 (95% CI 0.85 to 1.69) in vitamin K antagonist 
users, compared to non-users. 
Conclusion: In incident pre-dialysis patients, the use of vitamin K antagonists was not asso-
ciated with an accelerated kidney function decline or an earlier start of dialysis compared to 
non-use. The lack of knowledge on the indication for vitamin K antagonist use could lead to 
confounding by indication.
Keywords: coumarins, epidemiology, chronic kidney disease, glomerular filtration rate
Introduction
Vitamin K antagonists are used to prevent and treat thrombotic complications. Sev-
eral clinical trials performed in patients with thrombotic complications and a normal 
kidney function have shown that the benefits of vitamin K antagonists outweigh the 
side effects such as bleeding.1–4 
Recent studies have debated whether the benefits of vitamin K antagonists also 
outweigh the risks in patients with early stage chronic kidney disease or in dialysis 
patients.5–11 A post hoc analysis of a recent trial comparing direct oral anticoagulants 
with vitamin K antagonists showed that patients with a mildly decreased kidney func-
tion receiving vitamin K antagonists exhibited a greater decline in renal function than 
patients receiving direct oral anticoagulants.12 Furthermore, most studies in dialysis 
patients have failed to show a protective effect of vitamin K antagonists on stroke risk 
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or all-cause mortality,5–9,13 with the exception of two studies 
that showed a decreased risk of stroke and a survival benefit 
for vitamin K antagonists in dialysis patients.10,14 The pro-
posed hypotheses of these negative effects due to vitamin K 
antagonists are that the medication could either cause damage 
to the kidneys by vascular calcifications due to the inhibi-
tion of matrix Gla protein or cause damage by glomerular 
hemorrhage which could lead to tubular obstruction.11,15–19
As patients with chronic kidney disease are often pre-
scribed vitamin K antagonists, an adequate insight into the 
benefits and risks of vitamin K antagonist use is crucial.20 To 
our knowledge, there are no existing studies that investigated 
the association between vitamin K antagonist use and decline 
of glomerular filtration rate or time until start of dialysis in 
pre-dialysis patients with stage 4–5 chronic kidney disease. 
From a clinical point of view, withholding medication that 
could lead to kidney function decline is very important to 
postpone or prevent dialysis in pre-dialysis patients. 
Therefore, the aim of this study was to investigate the 
association between vitamin K antagonist use and the rate 
of kidney function decline and time until start of dialysis in 
incident pre-dialysis patients. 
Methods
Study design and population
The PREdialysis PAtient REcord (PREPARE) study29,30 is 
a multicenter follow-up study of incident patients starting 
specialized pre-dialysis care (age ≥18 years) in the Neth-
erlands. At inclusion, these patients had an estimated glo-
merular filtration rate (eGFR) between 20 and 30 mL/min 
per 1.73 m2 (chronic kidney disease [CKD] stages 4–5). The 
PREPARE study consists of a retrospective and a prospective 
cohort. In the retrospective cohort (PREPARE-I), incident 
pre-dialysis patients who had their first pre-dialysis visit 
between 1999 and 2001 were included from eight outpatient 
clinics. In the prospective cohort (PREPARE-II),31 incident 
pre-dialysis patients who started pre-dialysis care in one of 
the 25 participating outpatient clinics between 2004 and 
2011, and understood the Dutch language were included. In 
PREPARE-I, patients who experienced kidney failure from 
a kidney transplant were excluded. In PREPARE-II, patients 
who experienced kidney failure from a kidney transplant that 
was received within a year before referral to pre-dialysis 
care were excluded. The study was approved by the medical 
ethics committee or the institutional review board of the 
participating centers (Supplementary materials). Patients 
included in PREPARE-II gave written informed consent 
before study inclusion.
Demographic and clinical data
Data were collected from medical records and extracted from 
the hospital information systems. Data on demography, pri-
mary kidney disease, comorbidities, medication use including 
vitamin K antagonist use (phenprocoumon or acenocouma-
rol), and laboratory values were collected at baseline and dur-
ing routine visits to the pre-dialysis outpatient clinics. These 
visits took place at the start of specialized pre-dialysis care and 
when one of the study endpoints was reached. In PREPARE-II, 
data were also collected every 6 months at follow-up visits. 
The closest laboratory measurement performed within 90 days 
before or after the date of a visit was appointed to that visit. 
Patients were categorized as non-users or users of vitamin K 
antagonists based on medication use at baseline. We had no 
information about the indication for vitamin K antagonist use. 
The eGFR was calculated using the CKD-EPI (CKD Epide-
miology Collaboration) formula from 2009, taking age, sex, 
race, and serum creatinine into account.21 Hypertension was 
defined as a history of hypertension, a systolic blood pres-
sure ≥140 mmHg, or a diastolic blood pressure ≥90 mmHg 
at baseline.22 Cardiovascular disease (CVD) was defined as 
angina pectoris, myocardial infarction, heart failure, ischemic 
stroke, or claudication. Primary kidney disease was classified 
according to the codes of the European Renal Association-
European Dialysis and Transplantation Association.23 Patients 
were grouped into four classes of primary kidney disease: 
glomerulonephritis, diabetes mellitus, renal vascular disease, 
and other kidney diseases. 
Outcomes
In the PREPARE study, patients were followed until the start 
of renal replacement therapy (defined as dialysis or renal 
transplantation), death, loss to follow-up, refusal to further 
participate in the study (PREPARE-II), recovery of renal 
function, or the end of the study period (January 2008 for 
PREPARE-I and October 2016 for PREPARE-II), whichever 
came first. The main outcomes were change in the rate of kid-
ney function decline and the start of dialysis within 2 years. 
For the current study, the follow-up time was restricted to 
2 years; after this period, the number of patients at risk became 
too small.24,25 The date of dialysis initiation was collected from 
medical records. To calculate the kidney function decline 
rate, all available eGFR measurements from 3 months prior 
to inclusion until 2 years of follow-up were used. 
Statistical analyses
Baseline characteristics are presented stratified for vitamin 
K antagonist use. Continuous variables are described by 
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their median and interquartile range (IQR), and categorical 
variables are presented as percentages. 
Follow-up time was defined as the time between baseline 
and the start of dialysis, other renal replacement therapy, 
death, or withdrawal or end of follow-up (2 years). To esti-
mate the change of renal function decline rate in vitamin 
K antagonist users, compared to non-users, a linear mixed 
model (LMM) was used. This model takes the correla-
tion between eGFR measurements within each individual 
patient into account. Multivariable analysis was used to 
adjust for age, sex, race, diabetes mellitus, hypertension, 
cardiovascular disease, malignancy, gastro-intestinal prob-
lems, antiplatelet drug use, primary kidney disease, and 
hemoglobin levels.
The proportional hazard assumption was tested using 
a log minus log plot. Incidence rates of dialysis initiation 
within 2 years of follow-up were calculated for both vitamin 
K antagonist users and non-users. Survival curves for the start 
of dialysis were determined with the Kaplan–Meier method, 
stratifying for vitamin K antagonist use. We conducted Cox 
proportional hazards regression analyses, obtaining HR with 
95% CI to estimate the effect of vitamin K antagonist use 
on the start of dialysis. Analyses were adjusted for potential 
confounders, including age, sex, race, diabetes mellitus, 
hypertension, cardiovascular disease, malignancy, gastro-
intestinal problems, antiplatelet drug use, primary kidney 
disease, hemoglobin levels, and eGFR levels. 
Multiple imputation was used to impute missing potential 
confounders at baseline. To test the robustness of the results, 
several sensitivity analyses were performed. Analyses were 
repeated with stratification by PREPARE-I and PREPARE-II. 
Furthermore, we repeated the analyses without correcting for 
cardiovascular disease, since cardiovascular disease could 
be both a confounder and part of the causal pathway. Next, 
we added angiotensin converting enzyme inhibitor (ACEi), 
angiotensin II receptor blocker (ARB), systolic blood pres-
sure, and diastolic blood pressure to our linear mixed model. 
These variables could be both a confounder or part of the 
causal pathway. For the same reason, C-reactive protein 
(CRP), body mass index (BMI), albumin, and proteinuria 
were added as confounders in a sensitivity analysis. 
Next we restricted our analysis to patients who were 
persistent users or non-users of vitamin K antagonists during 
the entire study period, since changes in therapy during the 
follow-up period might dilute treatment effects. Then, we 
restricted our analyses to patients with cardiovascular disease. 
This could give an indication of the effects of confounding 
by indication. Finally, we performed our analyses with a 
follow-up period of 5 years. All analyses were performed 
using SPSS version 23.0 for Windows.
Results
Baseline characteristics
Of the 1,049 patients in PREPARE, 547 patients originate 
from PREPARE-I and 502 patients originate from PREPARE-
II. Vitamin K antagonist use was known for all PREPARE-I 
patients and for 437 PREPARE-II patients, resulting in 984 
patients. Of these patients, 101 used a vitamin K antagonist 
and 883 did not use a vitamin K antagonist. The baseline 
characteristics of these 984 patients are shown in Table 1. 
Vitamin K antagonist users were older, were more often male, 
had more cardiovascular disease, and used antiplatelet drugs 
less often than vitamin K antagonist non-users. In vitamin K 
antagonist users, 59% had missing values for the variable 
malignancy, 62% for gastro-intestinal disease, 20% for eGFR, 
and 22% for hemoglobin. In the vitamin K antagonist non-
users, this was 43% for malignancy, 43% for gastro-intestinal 
disease, 11% for eGFR, and 10% for hemoglobin. A total 
of 846 (96%) patients were persistent vitamin K antagonist 
non-users, and 86 (85%) patients were persistent vitamin K 
antagonist users during the entire study period.
Table 1 Baseline characteristics of vitamin K antagonist users 
and vitamin K antagonist non-users (N=984)
Characteristics Vitamin K  
antagonist 
users
N=101
Vitamin K 
antagonist 
non-users
N=883
Age (years) 74 (68–79) 63 (51–74)
Sex, female 29% 39%
Primary kidney disease
Diabetes mellitus 21% 15%
Glomerulonephritis 9% 12%
Renal vascular disease 39% 26%
Other 32% 48%
Cardiovascular diseasea 71% 47%
Malignancy 20% 11%
Gastro-intestinal disease 26% 31%
Hypertension 83% 90%
Antiplatelet drug use 2% 16%
eGFR (mL/min)b 14.1 (10.5–18.0) 12.5 (9.6–16.7)
Hemoglobin (mmol/L) 7.4 (6.7–8.1) 7.2 (6.5–7.9)
Notes: Continuous variables: median (interquartile range); aCardiovascular disease 
was defined as angina pectoris, myocardial infarction, heart failure, ischemic stroke, 
or claudication. beGFR (estimated glomerular filtration rate) was calculated using 
the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula 
from 2009.21 Missing: Users: Malignancy, 60; Gastro-intestinal disease, 63; eGFR, 
20; Hemoglobin, 22. Non-users: Malignancy, 379; Gastro-intestinal disease, 383; 
Hypertension, 1; eGFR, 93; Hemoglobin, 89.
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During follow-up, the occurrence of vascular cerebral 
complications was recorded. A total of six brain infarctions 
occurred, all in vitamin K antagonist non-users. A cerebral 
hematoma was diagnosed in five vitamin K antagonist non-
users and in one vitamin K antagonist user.
Vitamin K antagonist and decline of 
kidney function
During the first 2 years of follow-up, patients had on aver-
age 1.5 (SD 1.2) serum creatinine measurements. The mean 
change in kidney function was –1.45 (95% CI –1.80 to –1.10) 
mL/min/1.73 m2/year for the total group. Table 2 shows the 
difference in kidney function change between vitamin K 
antagonist users and non-users. The difference in kidney func-
tion change was –0.09 (95% CI –1.32 to 1.13) mL/min/1.73 
m2/year after adjustment (the minus indicates an extra change 
of 0.09 units in the vitamin K antagonist users). In absolute 
numbers, this means the change in vitamin K antagonist 
non-users was –3.23 mL/min/1.73 m2/year, and the change 
in vitamin K antagonist users–3.32 mL/min/1.73 m2/year.
Vitamin K antagonists and start of dialysis 
within 2 years
Incidence rates for start of dialysis were 47/100 person-years 
for vitamin K antagonist users and 46/100 person-years for 
non-users. During the 2 years of follow-up, 48 (48%) vitamin 
K antagonist users started dialysis, and 520 (59%) non-users 
started dialysis. Figure 1 shows the Kaplan–Meier for start 
of dialysis for vitamin K antagonist users and non-users. The 
crude and adjusted HRs for start of dialysis are presented 
in Table 3. As compared with no vitamin K antagonist use 
(reference category), pre-dialysis patients who used vita-
min K antagonists did not have an increased risk of start of 
dialysis (HR 1.20; 95% CI 0.85 to 1.69), adjusted for age, 
sex, race, diabetes mellitus, hypertension, cardiovascular 
disease, malignancy, gastro-intestinal problems, antiplatelet 
drug use, primary kidney disease, hemoglobin levels, and 
eGFR at baseline. 
Sensitivity analyses
After stratification for study cohort, the extra change in kid-
ney function in vitamin K antagonist users was 1.11 (–0.86 to 
3.07) mL/min/1.73 m2/year in PREPARE-I and –0.40 (–1.89 
to 1.09) mL/min/1.73 m2/year in PREPARE-II (Table S1). 
Vitamin K antagonist users in PREPARE-I had an HR for 
start of dialysis of 1.38 (95% CI 0.87 to 2.18) as compared 
with non-users, and in PREPARE-II, this was 1.09 (95% CI 
0.63 to 1.86) (Table S2). Performing the analyses without 
correction for cardiovascular disease resulted in an extra 
change in kidney function of –0.12 (95% CI –1.30 to 1.05) 
in vitamin K antagonist users and an HR for start of dialysis 
of 1.23 (0.88 to 1.73) as compared with non-users (Tables 
S3 and S4). Adding ACEi, ARB, systolic blood pressure, and 
Table 2 Vitamin K antagonist use and renal function decline
Mean decline in eGFR  
(mL/min/1.73 m2/year)
–1.45 (95%CI –1.80 to –1.10)
Change in decline in  
eGFR mL/min/1.73m2  
per year (95% CI)
Vitamin K antagonist non-users Reference
Vitamin K antagonist users, crude 0.43 (–0.74 to 1.60)
Vitamin K antagonist users, adjusteda –0.09 (–1.29 to 1.11)
Vitamin K antagonist users, adjustedb –0.09 (–1.32 to 1.13)
Notes: aAdjusted for age, sex, race, diabetes mellitus, hypertension, cardiovascular 
disease, malignancy, gastro-intestinal problems, antiplatelet drug use, and primary 
kidney disease; badditionally adjusted for hemoglobin levels.
Abbreviation: eGFR, estimated glomerular filtration rate.
Figure 1 Kaplan–Meier curves for start of dialysis stratified for vitamin K antagonist use.
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diastolic blood pressure to the linear mixed model changed 
the change in kidney function to –0.17 (95% CI –1.42 to 
1.08) (Table S3). The addition of CRP, BMI, albumin, and 
proteinuria changed the change in kidney function to 0.23 
(95% CI –1.74 to 2.20) (Table S3). The HR for start of 
dialysis changed to 0.80 (95% CI 0.37 to 1.74) (Table S4). 
Restricting the analyses to persistent users and non-users 
changed the adjusted change in kidney function to 0.15 (95% 
CI –1.17 to 1.47), in absolute numbers this means the change 
in vitamin K antagonist non-users was –2.41 mL/min/1.73 
m2/year, and the change in vitamin K antagonist users –2.26 
mL/min/1.73 m2/year (Table S5). The adjusted HR for start 
of dialysis changed to 1.36 (95% CI 0.96 to 1.93) in vitamin 
K antagonist users (Table S6). Restricting the analyses to 
patients with cardiovascular disease (417 non-users and 72 
users) resulted in an adjusted change in kidney function of 
0.07 (95% CI –1.50 to 1.64), which is –1.25 mL/min/1.73 
m2/year in vitamin K antagonist non-users and –1.18 mL/
min/1.73 m2/year in vitamin K antagonist users (Table S7). 
The adjusted HR for start of dialysis was 1.04 (0.66 to 1.65) 
in vitamin K antagonist users (Table S8). Using a follow-up 
period of 5 years changed the adjusted change in kidney 
function to 0.09 (95% CI –0.97 to 1.15), which means the 
absolute change in vitamin K antagonist non-users was –0.55 
mL/min/1.73 m2/year; in vitamin K antagonist users, this 
was –0.46 mL/min/1.73 m2/year (Table S9). The adjusted 
HR for start of dialysis was 0.99 (95% CI 0.98 to 0.99) for 
vitamin K antagonist users (Table S10). Figure S1 shows 
the Kaplan–Meier for start of dialysis stratified for vitamin 
K antagonist use for 5 years of follow-up.
Discussion
Key findings
In this cohort of 984 incident pre-dialysis patients with a 
follow-up of 2 years, we found no difference in annual kidney 
function decline between vitamin K antagonist users and non-
users. Furthermore, vitamin K antagonist use as  compared 
with non-use was not associated with an increased risk of 
start of dialysis within 2 years of follow-up. Restricting the 
population to patients with cardiovascular disease shows the 
same lack of an association for kidney function decline and 
risk of start of dialysis. All results should be viewed with 
the possible presence of confounding by indication in mind. 
Previous studies on the association 
between vitamin K antagonist use and 
kidney function decline and start of 
dialysis 
To our knowledge, there are no previous studies that investi-
gated the association between vitamin K antagonist use and 
kidney function decline in pre-dialysis patients. However, a 
post hoc analysis of the RE-LY trial (warfarin versus dabi-
gatran), in which patients with an eGFR <30 mL/min were 
excluded, showed that warfarin users had more kidney func-
tion decline over the first 30 months (–3.68 mL/min/1.73m2) 
than dabigatran users (–2.57 mL/min/1.73m2 with 110 µg and 
–2.46 mL/min/1.73m2 with 150 µg).12 The long-term effects 
of vitamin K antagonists on kidney function have not yet 
been investigated.
Vitamin K antagonists and start of dialysis
Although we did not find an association between vitamin K 
antagonist and start of dialysis within 2 years of follow-up, 
we did find a 1.2-fold increased risk with a wide confidence 
interval. It could be that vitamin K antagonist use, which 
is a marker for cardiovascular disease, is associated with 
dialysis initiation through pathways other than kidney func-
tion decline, including fluid overload. 
Pathophysiological effects of vitamin K 
antagonists on kidney
There are several pathophysiological mechanisms through 
which vitamin K antagonists could influence kidney function. 
Table 3 Vitamin K antagonist use and HRs for start of dialysis
Vitamin K antagonist use Person years Number of events HR (95% CI)
Vitamin K antagonist non-users 
N=883
988.7 65 1 (reference)
Vitamin K antagonist users, crude 
N=101
107.6 632 0.84 (0.62 to 1.13)
Vitamin K antagonist users, adjusteda  
N=101
0.91 (0.65 to 1.28)
Vitamin K antagonist users, adjustedb  
N=101
1.20 (0.85 to 1.69)
Notes: aAdjusted for age, sex, race, diabetes mellitus, hypertension, cardiovascular disease, malignancy, gastro-intestinal problems, antiplatelet drug use, and primary kidney 
disease; badditionally adjusted for hemoglobin and estimated glomerular filtration rate levels.
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First, vitamin K antagonists are associated with increased 
arterial calcifications and accelerate preexisting vascular 
calcifications due to the inhibition of matrix Gla protein. 
This could potentially lead to an acceleration of kidney 
dysfunction decline.17–19 Furthermore, vitamin K antagonist 
use can cause glomerular hemorrhage, with dysmorphic red 
blood cells and tubular red blood cell casts causing tubular 
obstruction and thereby kidney damage.11,15,16 However, in our 
pre-dialysis patients, we did not find an association between 
vitamin K antagonist use and kidney function decline.
Clinical implications
Our study results suggest that the effect of vitamin K antago-
nist use on kidney function decline and start of dialysis is 
probably limited. Therefore, based on our study, we do not 
recommend withholding vitamin K antagonists to slow kidney 
function decline or postpone dialysis. However, the possibility 
of confounding by indication should be taken into account 
when interpreting these results. Other benefits and risks of 
vitamin K antagonist use in pre-dialysis patients are not 
known, since existing trials have excluded these patients due 
to their high bleeding risk. Guidelines mention this knowledge 
gap concerning risks and benefits of anticoagulation with vita-
min K antagonists for stroke prevention, especially in dialysis 
patients.26 A recent meta-analysis showed that treatment with 
vitamin K antagonists was associated with a non-significant 
26% risk reduction of ischemic stroke, a 21% increase in total 
bleeding risk, and no effect on mortality.27
Strengths and limitations of this study 
The main strength of this study is the well-defined cohort 
of incident pre-dialysis patients who received standardized 
treatments and check-ups by nephrologists. A wide range of 
incident pre-dialysis patients was included, and all patient 
information was used to perform the analyses, making the 
results generalizable to the clinical practice of pre-dialysis 
care. The main limitation of this study is the possibility 
of confounding by indication when comparing vitamin K 
antagonist users with non-users in an observational study 
design. We cannot exclude the possibility that doctors antici-
pate renal effects when prescribing or withholding vitamin K 
antagonists. In that case, patients with a worse kidney func-
tion would receive vitamin K antagonists less often, leading 
to a possible underestimation of negative effects of vitamin 
K antagonists. We tried to minimize this problem by correct-
ing for multiple confounders, but cannot exclude residual 
confounding. Another limitation is the lack of information on 
the indication for vitamin K antagonist use in our  population. 
Therefore, it could be that vitamin K antagonists were used 
for other indications than atrial fibrillation. However, since 
atrial fibrillation has a 2–3 times higher prevalence in CKD 
patients, compared to the general population, it is likely that 
the indication for vitamin K antagonist use in most of our 
population was atrial fibrillation.28 Another limitation is the 
possible non-adherence of the vitamin K antagonist users. 
Medication adherence often is not 100%, which is very likely 
to be the case in this study too. Non-adherence can lead to an 
underestimation of the true effects of vitamin K antagonists. 
However, the adherence in this study is a representation of 
adherence in clinical practice and therefore gives an estimate 
of the expected effects in clinical practice. In addition, we had 
no information on the number of patients that experienced 
kidney failure after receiving a kidney transplant. A final 
limitation is the inclusion of prevalent vitamin K antagonist 
users, which could have led to an underestimation of the 
negative effects on kidney function and start of dialysis in 
vitamin K antagonist users. 
Conclusion
In conclusion, there was no association between vitamin 
K antagonist use and rate of renal function decline in our 
pre-dialysis population. Furthermore, this study showed no 
association between vitamin K antagonist use and time until 
start of dialysis in incident pre-dialysis patients. This study 
should be viewed with the possibility of confounding by 
indication in mind, which emphasizes the need for random-
ized controlled trials comparing vitamin K antagonists with 
placebo or direct oral anticoagulants in pre-dialysis patients 
to investigate their effect on kidney function decline. This 
would provide better insight into the adverse effects of vita-
min K antagonists and more personalized prescription of 
anticoagulant drugs in pre-dialysis patients.
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